ASSESSMENT OF MAIN LIPID METABOLISM INDICATORS IN PATIENTS WITH CHRONIC PANCREATITIS AND METABOLICALLY ASSOCIATED FATTY LIVER DISEASE

dc.contributor.author	D FATTY LIVER DISEASE Rakhmatullaeva G. K. Sadullaeva U. A. Abdunazarova Z. A. Tashkent State Medical University
dc.date.accessioned	2026-02-17T06:33:54Z
dc.date.available	2026-02-17T06:33:54Z
dc.date.issued	2026-02-16
dc.identifier.issn	2938-3765
dc.identifier.uri	http://repo.tma.uz/xmlui/handle/1/3077
dc.description.abstract	Abstract The prevalence of metabolic syndrome (MS), non-alcoholic fatty liver disease (NAFLD), and non- alcoholic fatty pancreatic disease (NAFPD) accounts for one-quarter to one-third of the world’s population. It has been proven that the key pathogenetic mechanisms of these conditions are disorders of lipid and carbohydrate metabolism. A high comorbidity between NAFLD and NAFPD has been demonstrated: 67.9% of patients with NAFPD were found to have hepatic steatosis, and 96.8% of patients with NAFLD were diagnosed with pancreatic steatosis.	en_US
dc.language.iso	en	en_US
dc.title	ASSESSMENT OF MAIN LIPID METABOLISM INDICATORS IN PATIENTS WITH CHRONIC PANCREATITIS AND METABOLICALLY ASSOCIATED FATTY LIVER DISEASE	en_US
dc.type	Article	en_US